infecti
bovin
rhinothrach
ibr
caus
bovin
herpesviru
infect
distribut
worldwid
either
alon
associ
respiratori
cattl
pathogen
caus
signific
econom
loss
livestock
industri
aim
work
valid
guinea
pig
model
altern
method
current
vaccin
potenc
test
calv
guinea
pig
immun
two
dose
vaccin
day
apart
sampl
day
post
vaccin
dpv
antibodi
ab
respons
vaccin
guinea
pig
measur
elisa
viru
neutral
vn
statist
compar
ab
respons
cattl
guinea
pig
model
show
doserespons
relationship
antigen
concentr
vaccin
abl
discrimin
among
vaccin
contain
log
differ
concentr
good
repeat
reproduc
cv
regress
analysi
ab
titer
obtain
guinea
pig
bovin
dpv
respect
allow
us
classifi
vaccin
three
potenc
categori
satisfactori
satisfactori
unsatisfactori
bovin
immun
vaccin
correspond
three
categori
experiment
challeng
viru
level
protect
measur
reduct
viru
shed
diseas
sever
correl
well
vaccin
categori
use
data
gener
experi
includ
vaccin
calv
guinea
pig
refer
vaccin
known
potenc
placebo
commerci
vaccin
subject
statist
analysi
concord
analysi
indic
almost
perfect
agreement
model
target
speci
ab
titer
measur
elisa
almost
perfect
substanti
agreement
ab
titer
measur
vn
taken
togeth
result
indic
develop
guinea
pig
model
repres
novel
reliabl
tool
estim
batchtobatch
vaccin
potenc
predict
efficaci
kill
veterinari
vaccin
infecti
bovin
rhinothrach
ibr
pustular
vulvovagin
ipv
respiratori
reproduct
diseas
domest
wild
cattl
caus
bovin
herpesviru
diseas
present
respiratori
form
includ
cough
nasal
discharg
conjunct
sign
rang
mild
sever
depend
presenc
secondari
bacteri
pneumoand
sweden
austria
denmark
part
itali
current
european
countri
compulsori
voluntari
erad
program
involv
applic
inactiv
live
marker
vaccin
base
delet
ge
gd
viral
glyprotein
rest
world
classic
attenu
kill
vaccin
commonli
appli
south
american
countri
like
argentina
brazil
uruguay
infect
endem
vaccin
mandatori
argentina
due
regulatori
restrict
kill
vaccin
use
prevent
viral
diseas
cattl
sever
convent
combin
inactiv
vaccin
contain
togeth
virus
bovin
viral
diarrhea
viru
bovin
parainfluenza
type
viru
bovin
respiratori
syncyti
viru
bacteri
pathogen
pasteurella
multocida
mannheimia
haemolytica
histophilu
sommi
moraxella
bovi
moraxella
ovi
campylobact
fetusfetu
campylobact
fetusvenereali
leptospira
sp
use
mani
decad
routin
vaccin
protocol
prevent
bovin
respiratori
reproduct
diseas
cattl
multival
vaccin
design
control
sanitari
problem
complex
etiolog
howev
potenc
efficaci
antigen
contain
combin
formul
unclear
studi
need
carri
properli
address
issu
specif
vaccin
approv
intern
regulatori
polici
recommend
evalu
vaccin
qualiti
potenc
test
conduct
seroneg
calv
vaccin
must
prevent
develop
sever
clinic
sign
markedli
reduc
viru
shed
experiment
challeng
bovin
trial
cumbersom
expens
time
consum
particularli
countri
like
argentina
well
viral
infect
endem
difficulti
find
seroneg
bovin
free
herd
use
vaccin
potenc
test
pose
need
develop
standard
harmon
test
laboratori
anim
avail
laboratori
anim
model
would
enabl
regulatori
author
vaccin
manufactur
carri
batchtobatch
releas
test
routin
basi
less
time
consum
less
expens
way
although
vaccin
manufactur
report
use
guinea
pig
intern
qualiti
test
evalu
vaccin
valid
method
vaccin
potenc
test
laboratori
anim
possess
demonstr
concord
target
speci
yet
avail
properli
valid
vaccin
potenc
test
especi
design
combin
vaccin
includ
inactiv
virus
also
requir
us
european
union
could
global
use
control
viral
vaccin
appli
cattl
although
sever
elisa
test
develop
determin
ab
probe
sensit
specif
viral
neutral
vn
test
latter
still
consid
gold
standard
techniqu
use
vaccin
potenc
test
gener
aim
project
develop
statist
valid
guinea
pig
model
use
veterinari
vaccin
potenc
test
model
specif
design
evalu
immunogen
virus
current
includ
combin
vaccin
cattl
bovin
parainfluenza
type
bovin
viral
diarrhea
viru
bovin
sinciti
viru
bovin
rotaviru
bovin
coronaviru
present
paper
report
statist
inhous
valid
guinea
pig
model
method
potenc
test
inactiv
ibr
vaccin
valid
involv
studi
kinet
ab
respons
anim
model
target
speci
regress
analysi
appli
doserespons
curv
defin
categori
vaccin
qualif
concord
analysi
laboratori
anim
model
natur
host
confirm
experiment
challeng
latter
result
obtain
indict
ab
titer
immun
guinea
pig
constitut
use
predict
tool
vaccin
efficaci
cattl
total
male
femal
beef
calv
aberdeen
angu
hereford
crossbre
includ
studi
vaccin
trial
conduct
beef
farm
locat
bueno
air
argentina
herd
without
previou
histori
vaccin
select
infect
endem
argentina
vaccin
evalu
seroneg
anim
free
herd
also
seroneg
seroposit
calv
endem
herd
order
consid
variabl
real
target
popul
trial
conduct
endem
farm
number
posit
neg
anim
randomli
distribut
treatment
group
initi
studi
statist
similar
prevaccin
mean
ab
titer
varianc
among
group
everi
trial
bovin
vaccin
two
dose
vaccin
day
apart
recommend
label
commerci
vaccin
test
vaccin
administ
subcutan
rout
dose
ml
accord
recommend
vaccin
formul
model
valid
name
refer
vaccin
appli
follow
time
interv
dose
volum
commerci
vaccin
blood
sampl
serum
extract
collect
punctur
jugular
coccyg
vein
anim
sampl
day
postvaccin
dpv
control
group
includ
placebo
nonvaccin
anim
group
calv
receiv
two
dose
placebo
formul
cultur
media
without
viru
emulsifi
oiladjuv
assay
eight
occas
includ
doserespons
trial
anim
sampl
dpv
addit
order
vaccin
nonvaccin
group
expos
similar
natur
condit
group
nonvaccin
calv
includ
everi
bovin
trial
conduct
farm
particip
studi
bovin
trial
consid
valid
includ
statist
analysi
seroconvers
detect
nonvaccin
placebo
control
group
experi
carri
blind
veterinarian
laboratori
technician
seroconvers
defin
increas
antibodi
titer
elisa
vn
laboratori
anim
model
vaccin
potenc
test
develop
use
total
guinea
pig
cavia
porcellu
si
al
around
g
weight
variou
preliminari
assay
use
differ
vaccin
rout
dose
volum
interv
dose
data
shown
immun
protocol
standard
follow
minimum
guinea
pig
vaccin
two
dose
vaccin
day
apart
intramuscular
rout
hindleg
volum
dose
administ
guinea
pig
correspond
volum
dose
given
bovin
doserespons
studi
serum
sampl
obtain
dpv
order
obtain
kinet
ab
respons
lab
anim
model
concord
studi
guinea
pig
sampl
dpv
blood
extract
conduct
cardiac
punctur
anesthesia
follow
ecvam
recommend
anim
welfar
protocol
approv
cicv
inta
ethic
committe
cicua
immun
assay
least
three
neg
control
anim
nonvaccin
vaccin
placebo
includ
guinea
pig
experiment
group
code
serolog
analys
carri
blind
viru
neutral
assay
use
studi
consid
gold
standard
tradit
test
perform
previous
describ
adjust
meet
recommend
given
oie
cfr
briefli
bovin
guinea
pig
serum
sampl
heat
inactiv
c
min
four
replic
serial
dilut
sampl
prepar
well
plate
mix
equal
volum
refer
strain
lo
angel
contain
tissu
cultur
infecti
dose
tcid
lead
final
neutral
stage
extra
sampl
replic
without
viru
use
evalu
potenti
toxic
serum
cell
posit
neg
control
sera
known
ab
titer
also
includ
assay
intern
refer
control
bovin
refer
sampl
deriv
natur
infect
vaccin
experiment
challeng
calv
previous
describ
guinea
pig
refer
sampl
obtain
natur
seroneg
vaccin
anim
detail
elsewher
serumviru
mixtur
incub
h
c
l
madin
darbi
bovin
kidney
mdbk
cell
suspens
contain
cell
ad
day
incub
c
plate
read
microscop
cytopathogen
effect
cpe
test
consid
valid
check
back
titrat
viru
gave
infecti
titer
tcid
accept
rang
tcid
posit
control
give
expect
titer
neg
serum
give
neutral
monolay
cpe
monolay
control
cell
cell
plu
cultur
medium
without
serum
without
viru
intact
viru
neutral
ab
titer
calcul
reed
muench
method
neg
serum
sampl
receiv
arbitrari
valu
calcul
purpos
enzym
link
immunosorb
assay
elisa
quantif
total
antibodi
bovin
guinea
pig
total
antibodi
bovin
serum
determin
use
indirect
elisa
previous
describ
briefli
elisa
plate
coat
l
posit
concentr
semipurifi
contain
tcid
ml
mock
infect
mdbk
cell
block
pbstween
ovoalbumin
buffer
serial
dilut
serum
sampl
ad
assay
develop
peroxidas
label
goat
anti
bovin
igg
affin
purifi
antibodi
kirkegaard
perri
laboratori
kpl
elisa
assay
adapt
detect
antibodi
guinea
pig
sera
follow
procedur
cite
use
goat
affin
purifi
anti
guinea
pig
igg
h
l
peroxidas
label
antibodi
kirkegaard
perri
laboratori
kpl
dilut
conjug
antibodi
titer
sampl
express
log
reciproc
highest
serum
dilut
correct
optic
densiti
od
od
posit
coat
well
minu
od
neg
coat
well
greater
cut
valu
assay
pp
speci
elisa
result
normal
express
correct
od
valu
percentag
singl
highposit
control
serum
pp
includ
plate
everi
elisa
run
valid
assay
fulfil
isoiec
requir
detail
elsewher
valid
method
vaccin
potenc
test
guinea
pig
conduct
follow
recommend
emea
committe
veterinari
medic
product
european
committe
altern
method
valid
ecvam
three
set
vaccin
consist
combin
waterinoil
vaccin
contain
increas
concentr
cover
rang
tcid
dose
two
vaccin
tcid
dose
togeth
fix
concentr
parainfluenza
type
bovin
viru
bovin
viral
diarrhea
viru
formul
viral
antigen
inactiv
use
binari
ethylenimin
bei
vaccin
formul
use
pilot
scale
equip
adjuv
use
formul
consist
mix
polisorb
sorbitan
monool
miner
oil
oil
water
proport
vaccin
set
formul
differ
dilut
bulk
antigen
previous
dilut
concentr
order
obtain
desir
ag
concentr
vaccin
formul
thereaft
vaccin
known
antigen
concentr
refer
refer
vaccin
use
estim
doserespons
calibr
curv
bovin
calv
guinea
pig
set
refer
vaccin
test
two
independ
experi
guinea
pig
two
independ
trial
bovin
calv
tabl
antibodi
respons
determin
vn
valid
elisa
initi
stage
develop
sampl
taken
differ
time
point
kinet
antibodi
respons
mean
elisa
vn
antibodi
titer
induc
first
set
refer
vaccin
calibr
vaccin
evalu
dpv
guinea
pig
dpv
calv
case
vaccin
administ
parallel
group
minimum
guinea
pig
bovin
minimum
number
repetit
anim
per
group
n
calcul
achiev
statist
power
least
discrimin
vaccin
contain
concentr
differ
log
kinet
antibodi
respons
select
sampl
time
point
detect
limit
comparison
model
target
speci
curv
kinet
antibodi
respons
vaccin
speci
analyz
use
mix
model
repeat
measur
bonferroni
method
multipl
comparison
analysi
allow
determin
earliest
time
point
anim
sampl
correspond
peak
plateau
ab
titer
also
show
accept
discriminatori
capac
second
stage
valid
time
point
select
previou
stage
abil
laboratori
anim
model
bovin
calv
significantli
discrimin
among
vaccin
formul
antigen
concentr
log
differ
evalu
stage
minim
antigen
concentr
induc
detect
ab
respons
elisa
vn
determin
detect
limit
minim
immunogen
dose
individu
assaytri
use
group
anim
analyz
oneway
analysi
varianc
anova
follow
dgc
multipl
comparison
test
kruskal
walli
nonparametr
rank
sum
test
use
assumpt
normal
andor
homoscedast
met
control
group
nonvaccin
placebo
group
consid
analysi
anim
group
remain
seroneg
throughout
experi
varianc
equal
zero
case
signific
level
establish
statist
analysi
vaccin
test
antigen
concentr
consid
experi
trial
involv
doserespons
studi
perform
nest
analysi
varianc
nest
anova
appli
model
allow
quantifi
rel
contribut
differ
sourc
variat
associ
repeat
reproduc
host
speci
guinea
pig
model
tabl
vaccin
test
parallel
bovin
guinea
pig
includ
concord
analysi
three
set
waterinoil
vaccin
decreas
concentr
beiinactiv
emulsifi
oil
adjuv
prepar
except
two
vaccin
test
vaccin
set
evalu
two
independ
experi
guinea
pig
two
independ
field
trial
bovin
group
includ
guinea
pig
bovin
except
vaccin
anim
ad
increas
number
replic
concentr
consid
condit
detect
limit
model
group
anim
vaccin
placebo
nonvaccin
includ
assay
neg
control
b
refer
vaccin
second
set
vaccin
known
antigen
concentr
potenc
prepar
industri
condit
use
concord
analysi
includ
waterinoil
emuls
c
oil
commerci
vaccin
includ
waterinoil
doubl
wateroilwat
emuls
vaccin
test
one
occas
evalu
stabil
time
gener
higher
number
comparison
line
evalu
vaccin
potenc
repeat
express
coeffici
variat
cv
overal
rel
variat
individu
bovin
calv
guinea
pig
within
group
reproduc
express
cv
overal
rel
variat
differ
group
vaccin
vaccin
contain
concentr
regress
analysi
establish
cutoff
vaccin
classif
vn
elisa
mean
ab
titer
group
bovin
calv
guinea
pig
immun
calibr
vaccin
formul
doserespons
assay
previous
select
time
point
analyz
regress
analysi
lower
limit
predict
interv
use
classif
criterion
establish
rang
vaccin
qualiti
accept
term
immunogen
potenc
speci
calcul
split
point
use
vaccin
classif
three
categori
unsatisfactori
satisfactori
satisfactori
protect
rate
vaccin
repres
categori
evalu
experiment
challeng
natur
host
evalu
perform
select
split
point
vaccin
classif
describ
section
agreement
guinea
pig
model
target
speci
two
concord
analys
carri
first
analysi
total
pair
group
vaccin
calv
guinea
pig
test
first
analysi
use
data
gener
group
anim
vaccin
calibr
vaccin
use
estim
doserespons
curv
describ
section
anoth
assay
includ
second
set
combin
waterinoil
immunogen
elabor
follow
industri
outlin
product
tcid
dose
vaccin
known
antigen
concentr
consequ
known
potenc
also
assign
refer
vaccin
includ
three
inactiv
ibrbvdv
oil
vaccin
use
prevent
bovin
reproduct
syndrom
gediva
vaccin
develop
argentina
three
multival
respiratori
vaccin
emulsifi
oil
adjuv
monool
miner
oil
oil
water
proport
eight
placebo
group
nonvaccin
group
consid
neg
refer
group
avoid
bia
second
analysi
calibr
vaccin
use
set
split
point
n
nonvaccin
group
subtract
n
commerci
vaccin
ad
instead
thu
pair
group
includ
assay
refer
vaccin
commerci
vaccin
correspond
neg
control
group
n
commerci
vaccin
includ
analysi
product
market
prevent
viral
conjunct
respiratori
reproduct
diseas
cattl
variou
manufactur
contain
unknown
titer
inactiv
tabl
case
vaccin
administ
parallel
guinea
pig
bovin
calv
per
group
tabl
concord
vaccin
qualiti
predict
guinea
pig
model
one
obtain
natur
host
estim
weight
kappa
coeffici
weight
kappa
give
differ
weight
disagr
accord
magnitud
discrep
avoid
weak
kappa
statist
take
account
degre
disagr
valu
weight
kappa
indic
moder
agreement
valu
substanti
agreement
valu
almost
perfect
agreement
challeng
experi
conduct
cicv
facil
previous
describ
briefli
seroneg
calv
vaccin
two
vaccin
classifi
guinea
pig
model
bovin
calv
satisfactori
satisfactori
potenc
evalu
anim
receiv
placebo
use
control
repres
unsatisfactori
vaccin
group
calv
vaccin
two
dose
vaccin
day
apart
dpv
anim
challeng
intranas
rout
viru
la
concentr
tcid
ml
calv
monitor
infect
diseas
develop
viru
infect
measur
durat
peak
titer
viru
shed
nasal
swab
also
repres
area
curv
infect
auci
obtain
plot
infecti
titer
viru
shed
day
challeng
diseas
measur
durat
sever
clinic
sign
ibr
also
repres
area
curv
clinic
sign
auc
obtain
plot
presenc
clinic
sign
day
challeng
auc
calcul
use
medcalc
version
statist
softwar
second
challeng
experi
initi
plannedwa
carri
calv
field
trial
receiv
set
calibr
vaccin
unexpect
low
ab
respons
develop
anim
part
valid
present
method
vaccin
test
laboratori
section
virolog
institut
inta
certifi
manag
system
fulfil
iso
requir
resolut
ar
qs
initi
program
isoiec
accredit
three
set
refer
vaccin
formul
increas
concentr
per
dose
tabl
use
estim
calibr
curv
test
two
independ
assay
guinea
pig
two
independ
trial
bovin
calv
give
total
point
concentr
two
set
vaccin
contain
highest
concentr
ticd
dose
test
give
total
four
replic
kinet
ab
respons
follow
dpv
depict
fig
mean
elisa
vn
ab
titer
immun
guinea
pig
obtain
experi
dpv
statist
analysi
anova
detail
supplementari
data
tabl
experi
carri
guinea
pig
consid
valid
includ
analysi
give
total
group
estim
regress
curv
doserespons
experi
bovin
calv
conduct
six
differ
herd
use
total
five
calv
per
treatment
group
first
set
vaccin
test
two
independ
trial
involv
seroneg
calv
two
free
farm
without
histori
previou
vaccin
epidemiolog
evid
infect
fig
set
vaccin
also
evalu
two
bovin
trial
first
experi
carri
use
select
seroneg
calv
endem
herd
second
nonvaccin
herd
histori
natur
infect
includ
seroneg
seroposit
calv
prevaccin
ab
titer
vn
elisa
final
set
vaccin
test
anoth
two
free
farm
mean
elisa
vn
antibodi
titer
independ
trial
dpv
statist
analysi
detail
supplementari
data
tabl
trial
conduct
bovin
calv
consid
valid
neg
control
group
calv
receiv
placebo
nonvaccin
calv
show
seroconvers
end
experi
calv
free
herd
remain
seroneg
calv
endem
herd
maintain
initi
ab
titer
huge
variat
ab
respons
vaccin
observ
differ
bovin
trial
elisa
ab
respons
calv
endem
herd
trial
highest
expect
prime
anim
ab
respons
neg
calv
free
farm
trial
intermedi
high
contrast
ab
respons
seroneg
calv
select
endem
herd
trial
remark
lower
regist
calv
deriv
free
herd
unexpect
result
trial
exclud
regress
analysi
howev
order
evalu
protect
confer
low
ab
respons
comparison
one
obtain
optim
ab
respons
anim
trial
challeng
control
condit
supplementari
fig
tabl
exclus
bovin
trial
meant
group
final
use
estim
calibr
curv
preliminari
studi
show
laboratori
anim
model
host
speci
could
discrimin
among
vaccin
formul
antigen
concentr
within
order
magnitud
exampl
vaccin
contain
tcid
per
dose
induc
similar
ab
respons
vaccin
tcid
induc
detect
statist
similar
ab
respons
vaccin
formul
tcid
induc
respons
guinea
pig
induc
detect
respons
bovin
data
shown
base
result
decid
estim
calibr
curv
use
vaccin
differ
log
antigen
concentr
also
recommend
dilut
rate
use
viru
titrat
assay
dpv
receiv
two
dose
vaccin
guinea
pig
develop
strong
ab
respons
clear
dosedepend
behavior
accord
ag
concentr
vaccin
observ
antibodi
titer
remain
high
constant
dpv
laboratori
anim
model
dpv
correspond
peak
ab
titer
earliest
time
point
maximum
discrimin
among
vaccin
differ
log
antigen
concentr
fig
vaccin
group
bovin
develop
ab
respons
dpv
time
point
correspond
peak
ab
titer
dpv
respons
remain
plateau
start
decreas
fig
shape
kinet
curv
ab
respons
speci
similar
ab
titer
detect
guinea
pig
dpv
compar
detect
bovin
dpv
thu
time
point
select
optim
moment
sampl
use
uniqu
bleed
point
concord
studi
futur
routin
use
guinea
pig
model
method
vaccin
potenc
test
detect
limit
discriminatori
abil
guinea
pig
model
target
speci
differenti
among
vaccin
formul
concentr
differ
log
dpv
guinea
pig
model
abl
discrimin
vaccin
formul
tcid
dose
higher
vaccin
contain
tcid
dose
tcid
dose
elisa
experi
vaccin
tcid
dose
induc
mean
ab
titer
higher
vaccin
contain
tcid
dose
induc
mean
ab
titer
lower
vaccin
formul
tcid
dose
induc
ab
respons
indic
condit
use
concentr
detect
limit
model
serolog
test
use
global
analysi
consid
total
number
guinea
pig
vaccin
ag
dose
show
guinea
pig
model
abl
significantli
differenti
among
vaccin
formul
concentr
differ
log
fig
group
calv
vaccin
decreas
dose
also
show
doserespons
effect
case
vaccin
formul
tcid
dose
higher
induc
ab
respons
vaccin
formul
tcid
dose
induc
detect
ab
respons
entir
period
trial
fig
supplementari
data
tabl
notabl
anim
trial
follow
dpv
seroconvers
detect
either
fig
ab
respons
measur
vn
tradit
techniqu
consist
yield
lower
ab
titer
obtain
elisa
speci
neutral
ab
respons
detect
group
anim
vaccin
tcid
indic
limit
detect
similar
techniqu
fig
supplementari
data
tabl
guinea
pig
model
gave
highli
consist
result
ab
titer
elisa
vn
among
differ
assay
ag
concentr
rang
tcid
dose
give
accept
repeat
reproduc
cv
associ
reproduc
test
less
antigen
concentr
test
tend
zero
variat
among
differ
assay
irrelev
vaccin
formul
tcid
dose
target
speci
also
gave
consist
result
test
potenc
vaccin
contain
tcid
dose
cv
associ
reproduc
techniqu
tabl
sinc
doserespons
experi
conduct
guinea
pig
five
six
trial
calv
consid
valid
total
group
laboratori
anim
model
group
host
speci
includ
regress
analysi
depict
fig
mean
antibodi
titer
determin
elisa
vn
directli
relat
concentr
vaccin
speci
techniqu
mathemat
model
best
fit
data
polynom
linear
model
second
order
magnitud
mathemat
model
abl
predict
elisa
ab
titer
r
guinea
pig
r
bovin
fig
case
vn
model
abl
predict
vn
ab
titer
guinea
pig
r
r
bovin
fig
predict
interv
calcul
use
lower
limit
ab
titer
induc
vaccin
formul
tcid
dose
qualiti
split
point
limit
repres
minimum
mean
ab
titer
must
induc
group
minimum
guinea
pig
calv
vaccin
waterinoil
vaccin
contain
ag
concentr
coverag
detail
fig
estim
split
point
allow
classif
vaccin
guinea
pig
model
target
speci
two
techniqu
unsatisfactori
satisfactori
satisfactori
potenc
concord
vaccin
qualiti
predict
guinea
pig
model
one
obtain
natur
host
elisa
vn
shown
tabl
initi
analysi
includ
group
anim
immun
vaccin
known
antigen
concentr
placebo
nonvaccin
control
group
assign
refer
group
gave
almost
perfect
agreement
vaccin
classif
model
target
speci
techniqu
tabl
b
exclud
pair
group
use
model
estim
vaccin
use
estim
calibr
curv
placebo
nonvaccin
control
group
ad
instead
commerci
vaccin
unknown
potenc
weight
kappa
valu
lower
tabl
nevertheless
agreement
remain
almost
perfect
elisa
substanti
vn
accord
criteria
establish
viera
et
al
final
commerci
vaccin
analyz
concord
guinea
pig
model
host
speci
almost
perfect
techniqu
supplementari
data
tabl
first
challeng
experi
tabl
placebo
anim
becam
infect
shed
high
titer
viru
nasal
secret
mean
peak
titer
tcid
ml
day
viru
tabl
concord
guinea
pig
model
bovin
analyz
elisa
vn
b
analysi
includ
assay
includ
vaccin
known
antigen
concentr
known
potenc
refer
refer
vaccin
assay
includ
commerci
vaccin
unknown
potenc
correspond
neg
control
group
n
challeng
anim
present
auci
develop
typic
sign
ibr
character
sever
bilater
rhiniti
auc
contrast
vaccin
anim
challeng
dpv
protect
shed
significantli
less
viru
develop
significantli
less
sever
diseas
compar
placebo
group
anim
vaccin
vaccin
show
significantli
higher
protect
ibr
infect
diseas
vaccin
vaccin
base
variabl
measur
tabl
significantli
differ
protect
rate
observ
vaccin
anim
associ
significantli
differ
mean
elisa
ab
titer
group
dpv
second
challeng
experi
signific
differ
vaccin
placebo
group
term
infect
clinic
sign
observ
statist
differ
detect
among
vaccin
group
howev
group
calv
mean
elisa
ab
titer
higher
establish
split
point
show
reduct
three
day
durat
viru
shed
supplementari
data
fig
tabl
potenc
defin
rel
activ
biolog
product
determin
test
method
conduct
final
product
describ
approv
regulatori
agenc
potenc
test
vaccin
batch
import
compon
control
test
conduct
final
product
confirm
consist
manufactur
ensur
batchtobatch
qualiti
specif
kill
vaccin
intern
regulatori
polici
recommend
evalu
vaccin
qualiti
potenc
test
conduct
seroneg
bovin
calv
briefli
first
batch
viru
inactiv
vaccin
test
five
calv
suscept
ibr
infect
neg
neutral
antibodi
calv
vaccin
follow
manufactur
recommend
typic
dose
day
apart
three
anim
left
nonvaccin
control
fourteen
day
second
dose
vaccin
least
vaccin
calv
develop
viru
neutral
ab
titer
higher
vaccin
reach
potenc
requir
undergo
challeng
test
intranas
rout
two
three
control
calv
develop
hyperthermia
clinic
sign
ibr
one
vaccin
calv
may
develop
clinic
sign
otherwis
vaccin
batch
consid
poor
qualiti
experiment
challeng
oie
also
request
vaccin
reduc
nasal
viru
shed
least
time
viru
excret
period
day
compar
control
calv
thu
releas
market
vaccin
must
prevent
develop
sever
clinic
sign
markedli
reduc
viru
shed
experiment
challeng
test
conduct
calv
expens
time
consum
use
routin
test
vaccin
batch
releas
countri
like
argentina
south
american
countri
like
brazil
uruguay
infect
endem
region
find
seroneg
bovin
free
herd
becom
increasingli
difficult
use
serolog
test
guinea
pig
natur
seroneg
repres
conveni
altern
method
evalu
batchtobatch
vaccin
potenc
align
initi
refin
reduc
replac
anim
experiment
ab
respons
guinea
pig
bovin
show
dosedepend
pattern
antigen
dose
condit
use
minimum
dose
antigen
capabl
induc
detect
ab
respons
detect
limit
minimum
immunogen
dose
order
tcid
dose
inactiv
waterinoil
formul
speci
measur
vn
elisa
quadrat
term
mathemat
equat
obtain
linear
regress
analysi
reflect
kinet
antibodi
respons
indic
certain
ab
titer
ab
respons
improv
addit
higher
dose
antigen
guinea
pig
model
abl
significantli
discrimin
vaccin
formul
ag
concentr
differ
log
show
good
repeat
reproduc
recommend
intern
guidelin
import
highlight
choic
test
vaccin
formul
antigen
concentr
differ
scale
base
preliminari
data
indic
discrimin
observ
vaccin
formul
antigen
concentr
within
order
magnitud
observ
might
relat
fact
infecti
titer
viru
antigen
use
vaccin
formul
well
viru
use
vn
assay
conduct
use
dilut
experiment
design
trial
conduct
bovin
calv
attempt
includ
possibl
sourc
variat
found
field
seroneg
anim
free
infect
herd
seroposit
anim
endem
herd
despit
high
variat
precis
target
speci
test
vaccin
contain
tcid
dose
show
cv
lower
indic
repeat
reproduc
vaccin
classif
natur
host
techniqu
vn
elisa
quit
accept
sampl
time
point
comparison
guinea
pig
model
target
speci
dpv
respect
repres
peak
plateau
ab
respons
vaccin
inactiv
vaccin
earliest
time
point
high
discrimin
capac
determin
split
point
gener
classif
criteria
one
step
develop
laboratori
anim
model
well
verif
predict
abil
target
speci
agreement
classif
vaccin
potenc
two
anim
speci
laboratori
anim
model
natur
host
base
split
point
excel
elisa
good
vn
indic
develop
guinea
pig
model
repres
good
tool
predict
vaccin
immunogen
bovin
concord
analysi
conduct
evalu
agreement
laboratori
anim
model
host
speci
vaccin
classif
differ
degre
misclassif
affect
vaccin
manufactur
farmer
regard
use
two
techniqu
elisa
vn
vaccin
classif
recommend
optim
method
reduc
classif
discrep
model
target
speci
exampl
first
concord
analysi
classif
two
vaccin
elisa
unsatisfactori
guinea
pig
model
classifi
satisfactori
natur
host
may
constitut
econom
harm
vaccin
manufactur
one
techniqu
consid
one
case
correspond
calibr
vaccin
contain
tcid
dose
misclassifi
guinea
pig
elisa
properli
classifi
model
host
speci
vn
one
nonvaccin
control
group
preexist
elisa
antibodi
case
guinea
pig
properli
classifi
group
unsatisfactori
techniqu
bovin
misclassifi
elisa
hand
analyz
agreement
speci
vn
one
vaccin
classifi
unsatisfactori
guinea
pig
satisfactori
bovin
calv
case
failur
guinea
pig
immun
verifi
sinc
vaccin
retest
twelv
month
later
properli
classifi
satisfactori
speci
techniqu
basi
incid
decid
includ
refer
vaccin
everi
immun
test
posit
control
everi
guinea
pig
immun
full
valid
transfer
model
classif
vaccin
satisfactori
satisfactori
actual
unsatisfactori
fail
protect
cattl
repres
risk
livestock
produc
kind
misclassif
occur
two
case
vn
due
technic
error
laboratori
mistak
given
vn
run
special
case
use
techniqu
elisa
vn
allow
clarifi
sourc
discrep
kind
misclassif
mean
import
harm
industri
vaccin
produc
sinc
qualiti
vaccin
classifi
within
categori
satisfactori
satisfactori
accept
regulatori
agenc
regard
second
concord
analysi
includ
commerci
vaccin
five
classifi
unsatisfactori
speci
techniqu
suggest
vaccin
manufactur
improv
qualiti
product
order
reach
propos
standard
vaccin
assign
differ
immunogen
categori
propos
statist
model
guinea
pig
calv
also
show
signific
differ
protect
infect
diseas
challeng
natur
host
despit
differenti
immunogen
efficaci
satisfactori
satisfactori
vaccin
abl
pass
oie
requir
approv
releas
regard
evalu
vaccin
efficaci
import
highlight
among
differ
output
measur
experiment
challeng
auci
best
indic
evalu
protect
challeng
also
agre
vaccin
categori
term
immunogen
potenc
second
challeng
experi
conduct
calv
set
trial
indic
protect
data
agreement
unexpectedli
low
ab
titer
develop
anim
calv
elisa
ab
titer
lower
select
cut
point
poor
protect
challeng
bovin
trial
disqualifi
vaccin
good
qualiti
although
bovin
select
trial
show
good
clinic
statu
bodi
condit
presenc
subclin
patholog
might
interfer
immun
respons
discard
may
affect
outcom
vaccin
efficaci
experi
natur
host
fact
commonli
observ
herd
vaccin
although
signific
progress
made
use
vitro
test
evalu
antigen
qualiti
paramet
model
measur
veterinari
vaccin
potenc
still
base
immunizationchalleng
assay
natur
host
laboratori
anim
use
vivo
model
vaccin
potenc
test
lotreleas
irreplac
moment
obtain
result
conclud
develop
guinea
pig
model
reliabl
tool
estim
batchtobatch
vaccin
potenc
avoid
problem
find
seroneg
bovin
endem
countri
reduc
variabl
found
bovin
significantli
reduc
cost
durat
test
model
also
ethic
compliant
refin
reduct
replac
principl
use
anim
also
take
part
new
consist
approach
serolog
result
guinea
pig
statist
valid
reliabl
indic
predict
vaccin
immunogen
protect
challeng
natur
host
interlaboratori
studi
progress
finish
full
valid
transfer
model
argentinean
nation
health
author
senasa
laboratori
anim
model
veterinari
viral
vaccin
potenc
test
one
propos
would
use
region
intern
regulatori
agenc
particular
propos
model
innov
sinc
design
evalu
kill
combin
vaccin
full
valid
allow
determin
one
immun
assay
use
guinea
pig
immunogen
viral
antigen
includ
vaccin
current
imarket
cattl
regard
argentinean
nation
author
start
test
use
develop
model
ibr
vaccin
potenc
test
control
vaccin
present
local
market
addit
valid
model
bovin
parainfluenza
type
rotaviru
complet
valid
bvdv
brsv
progress
